VPT:CC - Ventripoint Announced as Gold Sponsor for the 8th Annual Paediatric Echo Society Symposium
(TheNewswire)
Toronto, Ontario – The Newswire –September 08, 2023 - Ventripoint DiagnosticsLtd. (" Ventripoint " or the " Company "),(TSXV:VPT ) ( OTC:VPTDF) is pleased to announce its participation as a GoldSponsor for the highly anticipated 8 th AnnualPaediatric Echo Society Symposium. The event will take place inOrlando, Florida on September 9 th , 2023.
The Paediatric Echo Society Symposium, a nation-wideevent, is staged by Advent Health for cardiologists and sonographers.The symposium aims to foster collaboration, share cutting-edgeresearch, and discuss best practices in paediatric echocardiology. Thesymposium will feature an array of educational sessions, paneldiscussions, and demonstrations.
Ventripoint will have a prominent presence throughoutthe symposium, showcasing the latest diagnostic advancements of theVMS+ and hosting an interactive booth, offering attendees theopportunity to engage with the team and experience the VMS+.
“We are thrilled to be a sponsor for the8 th Annual Paediatric Echo Society Symposium,” said Dr. AlviraMacanovic, President and CEO of Ventripoint Diagnostics. “This eventpromises to be a great platform to exchange knowledge and experiencesamong experts in the field of paediatric cardiology.”
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson
416-669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.